NovoCure Limited
NasdaqGS:NVCR
$ 21.99
$0.00 (0.00%)
$ 21.99
$0.00 (0.00%)
End-of-day quote: 05/18/2024

NovoCure financials at a glance

The revenue of NovoCure is reported as 0.50934 billion Dollars in the fiscal year 2023. The earnings were -1.95 Dollars per share in 2023, which was 121.59 lower than 2022. And about -0.10043 billion Dollars are reported as free cash flow in the financials of NovoCure 2023. No dividends were paid to the shareholders of the NovoCure stock NasdaqGS:NVCR in the financial year 2023.

$509.34M
Revenue
$-1.95
Earnings Per Share
74.96%
Gross Margin %
$-,124.35M
Free Cash Flow
Revenue
509.34
Earnings Per Share
-1.95
Gross Margin %
74.96
Free Cash Flow
-,124.35

Financials

Year Year TTM 2023 2022 2021 2020 2019 2018 2017 2016 2015
Rev. Revenue N/A $509.34M $537.84M $535.03M $494.37M $351.32M $248.07M $177.03M $89.30M $66.90M
GM % Gross Margin % 75.40% 74.96% 78.76% 78.53% 78.54% 74.87% 67.87% 68.70% 51.93% 37.82%
OM Operating Margin -44.35% -44.40% -16.53% -8.29% 6.23% -0.17% -13.43% -22.11% -,127.02% 0.00%
EPS Earnings Per Share $-1.86 $-1.95 $-0.88 $-0.56 $0.20 $-0.07 $-0.69 $-0.70 $-1.47 $-1.32
Div. Dividends N/A $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
PR % Payout Ratio % 0 0 0 0 0 0 0 0 0 0
Sha. Shares N/AM 107.09M 105.46M 104.42M 102.41M 99.64M 94.99M 89.88M 87.07M 84.43M
OCF Operating Cash Flow N/A $-73.34M $30.79M $82.76M $99.15M $26.62M $-1.87M $-33.13M $-,107.59M $-99.88M
FCF Free Cash Flow N/A $-,124.35M $9.43M $58.59M $84.18M $16.14M $-8.58M $-40.50M $-,125.26M $-,110.16M
FCFS Free Cash Flow Per Share $-0.84 $-0.94 $0.09 $0.57 $0.83 $0.17 $-0.09 $-0.46 $-1.46 $-3.62